Keratinocytic skin cancers, referred to here as 'skin cancer', mostly comprise basal cell carcinoma (BCC) (approximately 75%)[@R1] and squamous cell carcinoma (SCC). These are the most commonly diagnosed cancers in the USA and UK.[@R2] [@R3] The annual incidence of skin cancer varies by latitude, age and sex. In New Hampshire, USA (1993--4) the age-adjusted rates per 100 000 population for BCC were 310 in men and 166 in women,[@R4] whereas in Arizona, USA (1996), corresponding rates for BCC were 936 and 497 in men and women, respectively.[@R5]

Some studies have found an increased risk of skin cancer in patients treated for rheumatoid arthritis (RA),[@R6] [@R7] whereas other studies have not.[@R8] [@R9] A Swedish study found no increased risk of SCC in a cohort of patients with early RA but did find a 66% increased risk in patients with prevalent RA.[@R10] The standardised incidence ratio (SIR) for SCC increased with the duration of follow-up, suggesting the risk may be related to cumulative RA duration and/or immunosuppressive therapy.

Anti-tumour necrosis factor (TNF) drugs have proved highly successful in treating RA. Five anti-TNF drugs are approved for use in North America and Europe; etanercept, adalimumab, infliximab, golimumab and certolizumab pegol. The introduction of TNF inhibitors has been accompanied by concerns regarding safety, and in particular the risk of malignancy.[@R11] As the most common malignancies are skin cancers, then if TNF inhibition does have an effect on the risk of malignancy, one might predict that the signal would be seen first in the skin. Data from clinical trials and observational studies in North America and Sweden have reported an increased risk of skin cancer with anti-TNF compared with the general population and untreated patients with RA.[@R10] [@R12]--[@R14]

The first aim of this study was to compare the incidence of skin cancer in anti-TNF-exposed and biological-naive patients with rates in the UK general population, using data from a national UK cohort of people with RA. The second aim was to explore the additional influence, if any, of anti-TNF therapy on the incidence of BCC and SCC by comparing incidence rates in these two cohorts.

Methods {#s1}
=======

Patients {#s2}
--------

The subjects\' written consent was obtained. The study was approved by the North-West Multicentre Research Ethics Committee. Subjects were participants in the British Society for Rheumatology Biologics Register (BSRBR), a national prospective observational study established in 2001 to monitor the long-term safety of biological therapy in RA. UK national guidelines recommend that anti-TNF is restricted to patients with active disease (defined as 28 joint disease activity score (DAS28) \>5.1) despite treatment with at least two non-biological disease-modifying antirheumatic drugs (nbDMARD), one of which should be methotrexate.[@R15] These guidelines recommend against the use of anti-TNF in patients with earlier malignancy within the previous decade. During the time period studied in this analysis, three anti-TNF agents were available in the UK: infliximab, etanercept and adalimumab. A comparison cohort of biological-naive RA patients was recruited in parallel and followed in an identical manner to the anti-TNF cohort.[@R16] These patients had active disease at recruitment (DAS28 ≥4.2) despite current treatment with at least one nbDMARD.

Patients were eligible if they had a physician diagnosis of RA and at least one returned rheumatologist follow-up questionnaire before 31 December 2008. The anti-TNF cohort was restricted to patients who received an anti-TNF as their first biological therapy and who registered with the BSRBR within 6 months of starting treatment. Patient-years of follow-up time were calculated from the date of starting an anti-TNF, or the date of registration with the BSRBR for the nbDMARD cohort. Follow-up was censored at the date of the most recently received hospital follow-up form before 31 December 2008 or death, if this came first. Patients were not censored at the point of skin cancer diagnosis, as they could be diagnosed with more than one skin cancer during follow-up. While only cancers diagnosed before 31 December 2008 were included in the analyses, we accepted all reports of such cancers up to 30 September 2010, to allow for any lag in cancer reporting to the BSRBR. Patients in the nbDMARD cohort who subsequently started an anti-TNF contributed follow-up time up until the date of the first dose of anti-TNF. As anti-TNF therapy may continue to influence the risk of skin cancer after its cessation, follow-up time after stopping anti-TNF was included in the analysis. Patients were censored from the analysis at the point of starting a biological disease-modifying antirheumatic drug other than anti-TNF.

Baseline assessment {#s3}
-------------------

Baseline data included demographics, disease duration, disease activity, current and past nbDMARD, comorbidities and smoking history. Patients completed a Stanford health assessment questionnaire (HAQ)[@R17] to indicate their level of physical disability. Previous malignancies, including skin cancers, were reported directly by the National Health Service Information Centre (NHS--IC) who link with the Office for National Statistics, which has been shown to register 90% of malignancies diagnosed in the UK accurately.[@R18] Registration of skin cancer is less complete as the UK Association of Cancer Registries suggests that only the first BCC or SCC per patient should be recorded.[@R19]

Follow-up {#s4}
---------

Changes to therapy were reported on rheumatologist questionnaires 6-monthly for 3 years, then annually thereafter. Data on adverse events were captured in three ways: from rheumatologist questionnaires; from 6-monthly patient diaries completed for 3 years; and by flagging with NHS--IC, which reported malignancies using the 10th edition of the International Classification of Diseases (ICD-10) and the International Classification of Diseases for Oncology, which distinguishes between BCC and SCC.

Additional information (including histology) was sought from physicians for all incident skin cancers. Two physicians (LKM and JBG) independently verified all reports of skin cancers. Skin cancers were verified if they were reported by NHS--IC or histology confirmed the diagnosis. Bowen\'s disease and known pre-existing skin cancers were excluded.

Statistical analysis {#s5}
--------------------

The risk of skin cancer in RA patients living in England was compared with the English general population. Age and gender-standardised rates of skin cancer for the entire UK population were not available and numbers of skin cancers occurring in BSRBR patients living in Northern Ireland, Scotland and Wales were insufficient for individual analyses. For England, SIR were calculated separately for the nbDMARD and anti-TNF cohorts. English population rates of skin cancer (excluding melanoma) from 2003 to 2008 were used. To ensure consistency between observed and expected rates we included only those cancers that had been reported to us from NHS--IC. Patients with a history of skin cancer before registration were included in this analysis because such patients could not be excluded from the population rates.

Risk comparisons were made between the anti-TNF and nbDMARD cohorts, first limited to patients without a previous history of skin cancer (BCC, SCC, melanoma or other skin cancer) at the time they joined the BSRBR. Rates of BCC and SCC are presented as total events per 100 000 patient-years with 95% CI. Survival analysis using Cox regression was used to compare the difference in risk between the anti-TNF and nbDMARD cohorts. Potential confounders were identified a priori and comprised potential risk factors for skin cancer (age, sex, smoking and previous exposure to ciclosporin and azathioprine), non-steroidal anti-inflammatory drugs (NSAID), as these have been shown to protect against skin cancer,[@R20] and differences in baseline characteristics (DAS28, HAQ, disease duration, baseline steroid use and year of entry to the study). Adjustment for these covariates was performed by calculating a propensity score, which reflected the likelihood that an individual patient was prescribed an anti-TNF given their known characteristics. The inverse of this score (or one minus the inverse for the nbDMARD cohort) was used as a weight in the Cox regression analysis. Missing baseline data were replaced using multiple imputations (see supplementary methods, available online only). The assumption of proportionality was tested using Schoenfeld residuals and met.

Individual comparisons of the anti-TNF agents with the nbDMARD cohort were made for BCC. A BCC was attributed to the anti-TNF prescribed at the time of skin cancer diagnosis, or to the most recently received anti-TNF. Three sensitivity analyses on the rate of BCC were planned in advance. First, an analysis was limited to the first BCC per patient only. Second, to investigate the effects of any possible screening bias, the first year of follow-up was excluded from the analysis. Third, an analysis was performed limited to patients with a previous history of reported BCC. No drug-specific analyses were performed for SCC. As SCC are rare in the UK population aged under 55 years,[@R21] [@R22] a sensitivity analysis for SCC restricted to patients aged over 55 years was performed. In addition to the main 'ever exposed to anti-TNF' analyses, rates of BCC and SCC in patients actively receiving anti-TNF, or within 90 days of stopping ('on drug'), were compared with nbDMARD. All analyses were conducted using Stata version 10.1.

Results {#s6}
=======

Three thousand six hundred and twenty-nine nbDMARD and 11 881 anti-TNF patients were included ([figure 1](#F1){ref-type="fig"}). The anti-TNF cohort was younger and comprised more women ([table 1](#T1){ref-type="table"}). Eighty-five per cent of patients were living in England. A known previous history of skin cancer was lower in the anti-TNF cohort (1.5% vs 2.9%). The anti-TNF cohort had more severe disease of longer duration. Two hundred and thirty-four patients enrolled in the nbDMARD cohort subsequently registered with the anti-TNF cohort and so contributed follow-up time to both. Twenty-four patients were censored from nbDMARD and 1327 from anti-TNF when starting other biological therapy.

![Flowchart showing selection of patients for the analysis. nbDMARD, non-biological disease-modifying antirheumatic drug; RA, rheumatoid arthritis; TNF, tumour necrosis factor.](ard-71-6-0869-fig1){#F1}

###### 

Baseline characteristics of patients

                                                                     First anti-TNF drug                
  ---------------------------------------- ----------- ------------- --------------------- ------------ ------------
  Mean age, years (SD)                     60 (12)     56 (12)       56 (12)               56 (12)      57 (12)
  Women, %                                 2621 (72)   9053 (76)     3193 (77)             2626 (76)    3234 (76)
  Country of residence (%)                                                                              
   England                                 3066 (84)   10 064 (85)   3572 (86)             3039 (87)    3453 (81)
   Northern Ireland                        365 (10)    299 (3)       45 (1)                56 (2)       198 (5)
   Scotland                                156 (4)     920 (8)       287 (7)               188 (5)      445 (10)
   Wales                                   42 (1)      598 (5)       235 (6)               192 (6)      171 (4)
  Smoking history, n (%)                                                                                
   Current smoker                          857 (24)    2580 (22)     846 (20)              757 (22)     977 (23)
   Former smoker                           1437 (40)   4510 (38)     1576 (38)             1314 (38)    1620 (38)
   Never smoked                            1317 (36)   4714 (40)     1691 (41)             1386 (40)    1637 (38)
   Not recorded                            18 (0)      77 (1)        26 (1)                18 (1)       33 (1)
  Ethnicity, n (%):                                                                                     
   White                                   2780 (77)   9829 (83)     3434 (83)             2814 (81)    3581 (84)
   Other                                   70 (2)      404 (3)       141 (3)               126 (4)      137 (3)
   Not recorded                            779 (21)    1648 (14)     564 (14)              535 (15)     549 (13)
  Skin cancer before registration, n (%)   106 (2.9)   177 (1.5)     68 (1.6)              40 (1.2)     69 (1.6)
  Mean DAS28 (SD)                          5.1 (1.3)   6.6 (1.0)     6.6 (1.0)             6.6 (1.0)    6.5 (1.0)
  Mean HAQ (SD)                            1.5 (0.8)   2.0 (0.6)     2.1 (0.6)             2.1 (0.5)    1.9 (0.6)
  Median disease duration, years (IQR)     6 (1, 15)   11 (6, 19)    12 (6, 19)            12 (6, 19)   10 (5, 18)
  Baseline steroid use, n (%)              831 (23)    5252 (44)     1979 (48)             1609 (46)    1664 (39)
  Baseline NSAID use, n (%)                1964 (54)   6976 (59)     2439 (58)             2513 (59)    2513 (59)
  Number of previous DMARD, median (IQR)   2 (1, 3)    4 (3, 5)      4 (3, 5)              4 (3, 5)     3 (3, 5)
  Ever exposed to azathioprine, n (%)      259 (7)     2474 (21)     1059 (26)             719 (21)     696 (16)
  Ever exposed to ciclosporin, n (%)       150 (4)     1943 (16)     792 (19)              704 (20)     447 (10)
  Entry year                                                                                            
   pre-2003                                8 (0)       1415 (12)     205 (5)               1180 (34)    30 (1)
   2003                                    309 (9)     311 (26)      1531 (37)             1106 (32)    479 (11)
   2004                                    891 (25)    3279 (28)     1978 (48)             506 (15)     795 (19)
   2005                                    925 (25)    1618 (14)     422 (10)              343 (10)     853 (20)
   2006                                    751 (21)    1137 (10)     2 (0)                 275 (8)      860 (20)
   2007                                    337 (9)     842 (7)       1 (0)                 65 (2)       776 (18)
   2008                                    408 (11)    474 (4)       0 (0)                 0 (0)        474 (11)

DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire; nbDMARD, non-biological disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; TNF, tumour necrosis factor.

Risk of skin cancer in patients with RA compared with the general population for England {#s7}
----------------------------------------------------------------------------------------

The SIR for overall skin cancer was similar and significantly increased in both treatment cohorts; SIR 1.72 (95% CI 1.43 to 2.04) anti-TNF; 1.83 (95% CI 1.30 to 2.50) nbDMARD ([table 2](#T2){ref-type="table"}). In the anti-TNF cohort, the SIR was higher for men than women (2.02, 95% CI 1.49 to 2.68 vs 1.57, 95% CI 1.24 to 1.96) whereas in the nbDMARD-only cohort the SIR was higher in women.

###### 

Standardised incidence ratios of NHS--IC reported skin cancers in England compared with England population 2003--8 (including patients with previous skin cancer)

             Skin cancer (excluding melanoma) ICD-10 C44           
  ---------- --------------------------------------------- ------- ---------------------
  nbDMARD    39                                            21.34   1.83 (1.30 to 2.50)
  Men        15                                            8.97    1.67 (0.94 to 2.76)
  Women      24                                            12.38   1.94 (1.24 to 2.89)
  Anti-TNF   126                                           73.44   1.72 (1.43 to 2.04)
  Men        48                                            23.79   2.02 (1.49 to 2.68)
  Women      78                                            49.65   1.57 (1.24 to 1.96)

ICD-10, International Classification of Diseases, 10th edition; nbDMARD, non-biological disease-modifying antirheumatic drug; NHS--IC, National Health Service Information Centre; SIR, standardised incidence ratio; TNF, tumour necrosis factor.

Risk of skin cancer for anti-TNF in patients without known past history of skin cancer {#s8}
--------------------------------------------------------------------------------------

This analysis included 14 993 patients. One thousand nine hundred and twenty-eight patients received more than one anti-TNF drug during follow-up. Two hundred and nineteen skin cancers were diagnosed during 53 140 patient-years of follow-up (176 in the anti-TNF cohort and 43 in the nbDMARD cohort ([tables 3](#T3){ref-type="table"},[4](#T4){ref-type="table"})). For anti-TNF, 19% of patients with incident skin cancer had multiple or recurrent lesions compared with 8% of the nbDMARD-only cohort (χ^2^ p=0.093). In the anti-TNF cohort, 121 (87%) first skin cancers were reported via NHS--IC compared with 36 (95%) in the nbDMARD cohort (χ^2^ p=0.185). One hundred and twenty-four (70%) of the skin cancers in the anti-TNF cohort occurred while the patient was receiving an anti-TNF drug. All skin cancers occurred in white patients.

###### 

Skin cancer reported in patients without previous history of skin cancer

                                                 nbDMARD   Anti-TNF   Etanercept   Infliximab   Adalimumab
  ---------------------------------------------- --------- ---------- ------------ ------------ ------------
  Number ever exposed to drug during follow-up   3523      11704      5086         3663         5035
  Patients with cancer                           38        139        54           49           36
  Cancers                                        43        176        67           67           42
  Patients with multiple cancers (%)             3 (8)     27 (19)    10 (18)      13 (27)      4 (11)
  BCC (%)                                        38 (88)   150 (85)   57 (85)      59 (88)      34 (81)
  SCC (%)                                        4 (9)     23 (13)    9 (13)       8 (12)       6 (14)
  Basosquamous cell carcinoma (%)                0 (0)     1 (1)      0 (0)        0 (0)        1 (2)
  Dermatofibrosarcoma protuberans                0 (0)     1 (1)      1 (1)        0 (0)        0 (0)
  Unclassified skin cancer (%)                   1 (2)     1 (1)      0 (0)        0 (0)        1 (2)
  First skin cancer reported by (%):                                                            
   NHS--IC                                       36 (95)   121 (87)   49 (91)      38 (78)      34 (94)
   Physician and/or patient                      17 (45)   85 (61)    35 (65)      33 (67)      17 (47)

BCC, basal cell carcinoma; nbDMARD, non-biological disease-modifying antirheumatic drug; NF, tumour necrosis factor; NHS--IC, National Health Service Information Centre; SCC, squamous cell carcinoma; TNF, tumour necrosis factor.

###### 

Risk of skin cancer for anti-TNF therapy in patients with RA without previous history of skin cancer

                                                                          BCC                SCC                                                                                                      
  ----------------------------------------------------------------------- ------------------ --------------------- --------------------- --------------------- --------------------- ---------------- ---------------------
  Number ever exposed to drug during follow-up                            3523               11 704                5086                  3663                  5035                  3523             11 704
  Exposure time (years)                                                   9342               43 798                19 108                11 700                12 991                9342             43 798
  Median exposure time per subject (years)                                2.65               4.01                  3.70                  2.70                  2.05                  2.65             4.01
  Patients with cancer                                                    34                 121                   47                    45                    29                    4                19
  Cancers                                                                 38                 150                   57                    59                    34                    4                23
  Incident rate/100 000 patient-years (95% CI)                            407 (288 to 558)   342 (290 to 402)      298 (226 to 387)      504 (384 to 650)      262 (181 to 366)      43 (12 to 110)   53 (33 to 79)
  Unadjusted HR (95% CI)                                                  Ref                0.84 (0.58 to 1.20)   0.71 (0.47 to 1.08)   1.25 (0.83 to 1.89)   0.64 (0.40 to 1.02)   Ref              0.93 (0.32 to 2.76)
  Age and gender HR (95% CI)                                              Ref                1.20 (0.83 to 1.73)   1.07 (0.70 to 1.63)   1.73 (1.14 to 2.62)   0.89 (0.56 to 1.42)   Ref              1.79 (0.59 to 5.41)
  aHR (95% CI)                                                            Ref                0.95 (0.53 to 1.71)   0.80 (0.44 to 1.47)   1.47 (0.76 to 2.85)   0.73 (0.37 to 1.46)   Ref              1.16 (0.35 to 3.84)
  First cancer per subject incident rate/100 000 patient-years (95% CI)   364 (252 to 509)   276 (229 to 330)      246 (181 to 328)      376 (273 to 505)      231 (156 to 330)                       
  First cancer per subject aHR (95% CI)                                   Ref                0.81 (0.45 to 1.48)   0.69 (0.37 to 1.29)   1.15 (0.60 to 2.21)   0.68 (0.33 to 1.38)                    
  Excluding first year of follow-up aHR (95% CI)                          Ref                1.18 (0.60 to 2.32)   1.05 (0.52 to 2.14)   1.70 (0.81 to 3.58)   0.91 (0.41 to 2.01)                    
  On drug analysis aHR (95% CI)                                           Ref                0.88 (0.48 to 1.60)   0.68 (0.36 to 1.29)   1.24 (0.63 to 2.46)   0.68 (0.32 to 1.42)   Ref              0.96 (0.28 to 3.32)

aHR, hazard ratio adjusted for inverse probability of treatment weighting; BCC,basal cell carcinoma; nbDMARD, non-biological disease-modifying antirheumatic drug; RA, rheumatoid arthritis; Ref, referent; SCC, squamous cell carcinoma; TNF, tumour necrosis factor.

### Basal cell carcinoma {#s9}

The unadjusted risk of BCC for anti-TNF compared with nbDMARD only was 0.84 (95% CI 0.58 to 1.20; [table 4](#T4){ref-type="table"}). Age, male gender, disease duration and previous exposure to azathioprine or ciclosporin were associated with a risk of BCC in univariate analysis (see supplementary table S1, available online only). Current smokers and patients taking NSAID at baseline were at reduced risk of BCC in univariate analysis. The fully adjusted HR for anti-TNF was 0.95 (95% CI 0.53 to 1.71). Analysis stratified by anti-TNF drug found a higher risk for infliximab than for the other two anti-TNF, although this was not statistically significant. The observed risk for infliximab was further attenuated in a sensitivity analysis limited to first BCC. After excluding the first year of follow-up, the HR for anti-TNF was not significantly increased (1.18, 95% CI 0.60 to 2.32).

### Squamous cell carcinoma {#s10}

The unadjusted HR for anti-TNF was 0.93 (95% CI 0.32 to 2.76; [table 4](#T4){ref-type="table"}). After adjustment for treatment weighting there was no association between anti-TNF and SCC (HR 1.16, 95% CI 0.35 to 3.84). When restricted to patients aged over 55 years the HR for anti-TNF was 1.32 (95% CI 0.33 to 5.32).

Risk of BCC in patients with known previous skin cancer {#s11}
-------------------------------------------------------

Two hundred and eighty-three patients had a history of skin cancer before entering the study (177 anti-TNF cohort; 106 nbDMARD cohort). The crude incidence rate of BCC was 10-fold higher in this cohort compared with those without previous cancer, and higher in the nbDMARD cohort compared with anti-TNF (7982 per 100 000 patient-years vs 4623 per 100 000 patient-years). The adjusted risk for anti-TNF was 0.70 (95% CI 0.26 to 1.94).

Discussion {#s12}
==========

The BSRBR is the largest biologicals register of its kind, with detailed follow-up for a median of 4 years and up to 8 years. The study has the unique advantage of the flagging of patients with the NHS--IC that provided details of all registered previous and incident BCC and SCC. The results show that compared with the general English population, the overall risk of skin cancer was increased in patients treated for RA, regardless of treatment history.

Our findings add to the results of several observational studies of RA.[@R6]--[@R8] [@R10] [@R23]--[@R25] A Danish study found a 40% increased risk of SCC and 30% relative increase in BCC.[@R7] However, this finding has not been consistent, and studies from Finland, Sweden and Scotland have not reported an increased risk.[@R6] [@R8] [@R23] An explanation for the increased skin cancer in the BSRBR cohort may be that that study comprised individuals with long-standing RA with high disease activity at baseline, all of whom have been exposed to disease-modifying antirheumatic drugs. The results may not be generalisable to patients with mild disease.

Other reasons for differing results may also include variations in definitions of skin cancer (with melanoma, SCC, BCC and other cancers being variably combined) and different methods of case ascertainment. We used English population data from 2003 to 2008, during which time it has been acknowledged that the reporting of skin cancers to the national registry was incomplete.[@R26] We only included cancers that were reported to us via NHS--IC in this analysis to account for this, meaning any underreporting would occur equally and introduce no bias. However, we found reporting of first skin cancers via NHS--IC to be similar in both cohorts; nbDMARD only 95% and anti-TNF 87%. In comparison, fewer cancers were physician reported, which may reflect the fact that most skin cancers are diagnosed in primary care or dermatology clinics and may not have been recorded in rheumatology casenotes.

In patients without reported previous skin cancer we found that the addition of anti-TNF did not exacerbate their risk of skin cancer when compared with nbDMARD alone with follow-up for several years. This is in keeping with a meta-analysis of randomised controlled trials of anti-TNF in RA.[@R27] Conversely, another randomised controlled trial meta-analysis of anti-TNF across all indications found a twofold increased risk of skin cancer.[@R12] In addition, an earlier analysis of BSRBR data, published in abstract form,[@R28] reported a possible signal for an increased risk of skin cancer. This earlier analysis relied more heavily on cancer reporting by the physicians as we only allowed a 6-month time lag for NHS--IC reporting. This may have increased the effect of reporting bias whereby physicians preferentially reported adverse events in patients treated with biological agents, perhaps demonstrated by the lower proportion of cases reported by the physician in the nbDMARD cohort. The updated analysis presented here allows for up to a 21-month lag in reporting by the NHS--IC and more complete case ascertainment by this source, as regional cancer registries are allowed up to 18 months to report cancers to the Office for National Statistics.[@R29] As this source is blind to the treatment arm of patients, it is less susceptible to bias, although a general surveillance bias among patients treated with anti-TNF therapies cannot be completely excluded.

In this study we also compared the risk of skin cancer between individual drugs. There was a suggestion that the incidence of BCC was higher for infliximab compared with nbDMARD than for etanercept or adalimumab, although this finding did not reach statistical significance. A US study found an increased risk of skin cancer for infliximab (OR 1.7, 95% CI 1.3 to 2.2) but not for etanercept (1.2, 95% CI 1.0 to 1.5) or adalimumab (0.9, 95% CI 0.5 to 1.8).[@R13] That study was unable to distinguish between BCC and SCC, which makes interpretation difficult given their different pathobiologies. Furthermore, in that study cases of malignancy were patient reported and not always histologically confirmed.[@R13]

In our study, the higher rate for infliximab may be partly explained by a small number of infliximab patients being diagnosed with multiple BCC, as the HR for infliximab was attenuated when the analysis was limited to first skin cancer. Surveillance bias may also explain this finding, as infliximab-treated patients were assessed every 8 weeks before each infliximab infusion: a hypothesis further strengthened by the higher rate of physician-reported events in patients receiving infliximab.

An important consideration of this study relates to the SCC risk in the anti-TNF cohort. Given that SCC is uncommon in the UK, this study may lack power to detect an important increased risk following anti-TNF. An indication that this may be case was that the HR for anti-TNF was higher when restricted to patients aged over 55 years. It is also important to bear in mind that in the UK, a history of previous malignancy is listed as a contraindication to anti-TNF. The finding of a 10-fold higher incidence of BCC in patients with previous BCC was in keeping with data from the general population.[@R30]

As with any observational study, it is important to acknowledge the potential for unmeasured confounding. We have collected detailed patient data at baseline for which we have made adjustments. We lack data on factors such as exposure to ultraviolet light or skin type.

Conclusions {#s13}
===========

Despite the difficulties in determining valid population rates of skin cancer, the findings from this study add weight to the evidence that skin cancers are increased among treated patients with RA, although it cannot support the hypothesis that anti-TNF therapy specifically increases this risk of BCC. An increased risk of SCC cannot be excluded. Recommendations for skin cancer prevention in the general population, such as sun avoidance, apply to patients with RA. These data support the regular monitoring of patients with RA for unusual or new skin lesions.
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